Popular GLP-1 weight-loss drugs may not just shrink waistlines; they may also quietly blunt the cravings that drive America’s addiction and overdose crisis.[1][3]
Story Snapshot
- A huge Veterans Affairs study of more than 600,000 people found GLP-1 drugs were linked to lower risks of new substance use disorders across every major drug category.[2][3][5]
- Veterans already battling addiction had fewer overdoses, emergency visits, hospitalizations, and drug-related deaths while on GLP-1 medications.[1][3]
- Researchers suspect these drugs dampen “craving” in the brain’s reward circuits, not just appetite in the gut.[3][6]
- The findings are promising but observational, meaning correlation, not yet rock-solid proof of causation.[2][5]
A diabetes and weight-loss drug that unexpectedly touches addiction
Doctors first prescribed glucagon-like peptide-1 receptor agonist drugs to control blood sugar in type 2 diabetes, and later to help people lose weight.[1][3] These medications, which include well-known brands built on semaglutide and similar compounds, mimic a natural hormone that reduces appetite and slows digestion, leading many patients to eat less and lose substantial weight.[2] As these drugs spread, patients and clinicians began reporting something harder to measure but impossible to ignore: cravings for alcohol or nicotine seemed to fade.[3][6]
Researchers at Washington University School of Medicine in St. Louis decided to test whether those anecdotal reports lined up with real-world outcomes.[3][6] They analyzed health records from more than 600,000 United States veterans with type 2 diabetes who started either a GLP-1 medication or another modern diabetes drug class.[2][3][5] Veterans offer a sobering but important population: higher rates of chronic pain, mental health conditions, and substance use compared with the general public mean more addiction risk—and more chances to see patterns.[1][3][5]
What the massive Veterans Affairs study actually found
Among over 520,000 veterans who did not have a diagnosed substance use disorder at the start, those on GLP-1 drugs were less likely to develop one over the next three years.[3][5] The risk of any new substance use disorder was about 14 percent lower than in those on other diabetes drugs, translating to roughly seven fewer new addiction diagnoses for every 1,000 GLP-1 users.[1][3] That difference showed up across alcohol, nicotine, cannabis, cocaine, opioids, and other drugs, not just one substance.[2][3][5]
The signals were even more striking in the roughly 80,000 veterans who already had a substance use disorder when they started treatment.[2][3] In that group, GLP-1 users had fewer addiction-related emergencies and serious consequences than their peers.[1][3] After three years, researchers reported about 30 percent fewer emergency department visits, 25 percent fewer hospitalizations, 40 percent fewer overdoses, and about 50 percent fewer drug-related deaths, equivalent to roughly 12 fewer serious addiction-related events per 1,000 GLP-1 users.[1][3][5]
How could a gut hormone drug touch the brain’s craving circuits?
The Washington University team and others argue that these results fit a broader scientific story about how GLP-1 works beyond the pancreas and stomach.[3][6] GLP-1 receptors sit in brain regions involved in reward, learning, and motivation, the very circuits hijacked by addictive drugs.[6] Animal and early human research suggests GLP-1 signaling can reduce the rewarding “pull” of substances, tamp down dopamine surges tied to cues, and make compulsive seeking behavior less likely, in the same way it makes overeating less compelling.[3][6]
Patients on GLP-1 medications frequently report feeling unexpectedly indifferent to alcoholic drinks or cigarettes they once wanted daily.[3][6] Those narratives align with the study’s cross-substance pattern: lowered risks across alcohol, nicotine, opioids, cannabis, cocaine, and more.[2][3][5] From a common-sense, conservative perspective, the biologic plausibility matters. A claim that one drug magically cures every addiction would ring hollow; a claim that it dampens a shared craving pathway lines up better with both neuroscience and restraint about miracle cures.[3][6]
Association is not destiny: why the skeptics are not wrong
The authors themselves emphasize a crucial caveat: this was an observational study using medical records, not a randomized clinical trial.[2][5] People on GLP-1 drugs may differ from those on other medications in ways that also reduce addiction risk, such as more motivated lifestyle changes, closer medical follow-up, or different underlying health profiles.[1][2][5] Statistical methods can adjust for many differences, but they cannot guarantee that all confounding factors are removed.[2]
A massive study of more than 600,000 U.S. veterans suggests that popular GLP-1 drugs such as semaglutide may do far more than help with diabetes and weight loss—they could also fight addiction itself. Researchers found that people taking these medications https://t.co/Sh41uVJ2pr
— Michael W. Deem (@Michael_W_Deem) June 3, 2026
Effect sizes, while meaningful, are modest in absolute terms—single-digit fewer new substance use disorders and low double-digit fewer severe events per 1,000 people over three years.[2][3] Those numbers matter at a population scale but do not turn GLP-1 drugs into standalone addiction cures.
What this could mean for addiction policy and personal decisions
For policymakers staring at overdose statistics and strained treatment systems, a diabetes drug that nudges addiction risk down across multiple substances is a tempting tool.[1][3][5] But responsible health policy waits for confirmatory trials, especially when the drugs are expensive and already in short supply for people with diabetes. A rush to label GLP-1s as anti-addiction pills could fuel off-label prescribing frenzies, worsen shortages, and expose patients to side effects without clear benefit.[2][4][6]
For individuals already taking a GLP-1 medication for diabetes or weight loss, the take-away is more grounded. If cravings ease and substance use drops, that is a welcome bonus, not a license to skip accountability or professional help.[3][4] For those battling addiction without diabetes or obesity, these findings are a reason to watch the research, not to self-experiment through compounded products or unregulated online sellers—a path that regulators and poison centers already link to dangerous dosing errors and overdoses.[2][5]
Sources:
[1] Web – Popular GLP-1 weight-loss drugs linked to lower risks of addiction and …
[2] Web – GLP-1 drugs linked to lower addiction rates in large study of veterans
[3] Web – Glucagon-like peptide-1 receptor agonists and risk of substance use …
[4] Web – National Helpline for Mental Health, Drug, Alcohol Issues – SAMHSA
[5] Web – VA Study: Ozempic, Other GLP-1 Drugs May Fight Addiction Across …
[6] Web – GLP-1 medications get at the heart of addiction: study
